The American Society of Breast Surgeons released its updated 2026 Resource Guide on March 9 2026, recommending cryoablation as a treatment option for selected patients with biologically low‑risk early‑stage breast cancer. The guide specifically cites IceCure Medical’s ProSense system, the only FDA‑cleared device for this indication, as a validated, cosmetically favorable alternative to surgical lumpectomy.
The endorsement follows the October 2025 FDA clearance and the positive outcomes reported in the ICE3 trial, which demonstrated non‑inferior local control and superior cosmetic results compared with standard surgery in women aged 70 and older with tumors up to 1.5 cm who receive adjuvant endocrine therapy.
IceCure’s CEO Eyal Shamir said the ASBrS recognition “further validates cryoablation’s role in modern breast cancer care and positions ProSense® as an option that prioritizes outcomes, cosmetic results, and patient choice.” The company expects the recommendation to increase referrals from breast surgeons and interventional radiologists, accelerating the adoption curve in the United States.
The ASBrS endorsement is a significant regulatory milestone that can shift physician practice patterns and expand the addressable market for cryoablation. By aligning with the society’s emphasis on preservation, de‑escalation, and individualized care, the recommendation supports broader acceptance of minimally invasive treatment and strengthens IceCure’s competitive position in a market projected to reach 200,000 eligible women annually.
While the endorsement does not immediately translate into sales figures, it is expected to drive demand for ProSense placements and procedure volumes, providing a foundation for future revenue growth as the company continues to expand its clinical evidence base and pursue reimbursement pathways.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.